CATALYST PHARMACEUTICALS, INC. (CPRX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, CATALYST PHARMACEUTICALS, INC. reported revenue of $588.99M, up 19.8% from the prior year. The company was profitable, with a net margin of 36.4%. It held $1.10B in total assets against $149.71M in total liabilities.
Key ratios (FY2025)
43.8%
Operating margin
36.4%
Net margin
22.5%
Return on equity
+19.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $588.99M | $491.73M | $398.20M | $214.20M | $140.83M | $119.07M | $102.31M | — | — | — |
| Cost of Revenue | $87.25M | $68.84M | $51.97M | $34.39M | $21.88M | $17.04M | $14.76M | — | — | — |
| Operating Income | $257.78M | $195.12M | $86.81M | $101.84M | $52.38M | $41.30M | $31.82M | -$35.30M | -$18.68M | -$19.28M |
| Net Income | $214.33M | $163.89M | $71.41M | $83.08M | $39.48M | $74.98M | $31.88M | -$34.00M | -$18.41M | -$18.07M |
| EPS (Diluted) | $1.68 | $1.31 | $0.63 | $0.75 | $0.37 | $0.71 | $0.30 | $-0.33 | — | — |
| Total Assets | $1.10B | $851.41M | $470.11M | $375.63M | $237.79M | $192.35M | $112.38M | $60.45M | $85.39M | $41.71M |
| Total Liabilities | $149.71M | $123.78M | $82.23M | $75.21M | $30.96M | $22.76M | $24.75M | $9.67M | $4.42M | $2.40M |
| Shareholders' Equity | $954.27M | $727.63M | $387.88M | $300.42M | $206.83M | $169.60M | $87.63M | $50.78M | $80.96M | $39.31M |
| Cash & Equivalents | $709.17M | $517.55M | $137.64M | $298.39M | $171.44M | $130.24M | $89.51M | $16.56M | $57.50M | $13.89M |
| Operating Cash Flow | $208.67M | $239.81M | $143.60M | $116.05M | $60.37M | $45.03M | $34.61M | -$26.15M | -$13.74M | — |
| Capital Expenditures | $58.0K | $556.0K | $231.0K | $29.0K | $1.02M | $11.0K | $19.0K | $92.0K | — | $96.1K |
| Shares Outstanding | 122.51M | 120.88M | 107.12M | 105.26M | 102.99M | 103.78M | 103.40M | 102.74M | 102.55M | 82.97M |